title: Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
abstract: Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The aim of the present study was to investigate the protective and restorative potential of magnolol, a major bioactive biphenolic from the bark of Magnolia officinalis, for alleviating the motor deficits induced by 6-hydroxydopamine (6-OHDA) in a mouse model of PD. Before or after unilateral striatal 6-OHDA lesion induction, mice were administered magnolol subchronically; then the apomorphine-induced rotational behaviors of the hemiparkinsonian mice and tyrosine hydroxylase (TH) expression in striatum were determined. Magnolol that was administered 30 min before 6-OHDA lesion induction and then applied daily for 14 days significantly ameliorated apomorphine-induced contralateral rotation in 6-OHDA-lesioned mice, and consistently protected the decreased levels of TH protein expression in striatum. One week after termination of the 7-day subchronic pretreatment, magnolol also remarkably prevented the dopaminergic neuronal loss as identified by TH immunohistochemistry staining in striatum, associated with rotational behavioral protection in 6-OHDA-lesioned mice. Importantly, daily subchronic posttreatment with magnolol for 14 days efficiently reduced apomorphine-induced rotation, but did not restore the neuronal impairment in striatum damaged by 6-OHDA. Taken together, these findings suggest that magnolol may possess neuronal protective activity and behavioral restoration against 6-OHDA-induced toxicity in the PD model.
authors.affiliation: Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan, ROC.
authors.forename: Hwei-Hsien
authors.initials: HH
authors.lastname: Chen
authors.forename: Shiau-Chin
authors.initials: SC
authors.lastname: Lin
authors.forename: Ming-Huan
authors.initials: MH
authors.lastname: Chan
mesh_terms: D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D017705:Lignans / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D016627:Oxidopamine / Q000037:antagonists & inhibitors / Q000633:toxicity*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D001713:Biphenyl Compounds; D017705:Lignans; D018696:Neuroprotective Agents; C005498:magnolol; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase